Elder J H, McGee J S, Munson M, Houghten R A, Kloetzer W, Bittle J L, Grant C K
J Virol. 1987 Jan;61(1):8-15. doi: 10.1128/JVI.61.1.8-15.1987.
We synthesized 27 synthetic peptides corresponding to approximately 80% of the sequences encoding gp70 and p15E of Gardner-Arnstein feline leukemia virus (FeLV) subtype B. The peptides were conjugated to keyhole limpet hemocyanin and injected into rabbits for preparation of antipeptide antisera. These sera were then tested for their ability to neutralize a broad range of FeLV isolates in vitro. Eight peptides elicited neutralizing responses against subtype B isolates. Five of these peptides corresponded to sequences of gp70 and three to p15E. The ability of these antipeptide antisera to neutralize FeLV subtypes A and C varied. In certain circumstances, failure to neutralize a particular isolate corresponded to sequence changes within the corresponding peptide region. However, four antibodies which preferentially neutralized the subtype B viruses were directed to epitopes in common with Sarma subtype C virus. These results suggest that distal changes in certain subtypes (possibly glycosylation differences) alter the availability of certain epitopes in one virus isolate relative to another. We prepared a "nest" of overlapping peptides corresponding to one of the neutralizing regions of gp70 and performed slot blot analyses with both antipeptide antibodies and a monoclonal antibody which recognized this epitope. We were able to define a five-amino-acid sequence required for reactivity. Comparisons were made between an anti-synthetic peptide antibody and a monoclonal antibody reactive to this epitope for the ability to bind both peptide and virus, as well as to neutralize virus in vitro. Both the anti-synthetic peptide and the monoclonal antibodies bound peptide and virus to high titers. However, the monoclonal antibody had a 4-fold-higher titer against virus and a 10-fold-higher neutralizing titer than did the anti-synthetic peptide antibody. Competition assays were performed with these two antibodies adjusted to equivalent antivirus titers against intact virions affixed to tissue culture plates. The monoclonal antibody had a greater ability to compete for virus binding, which suggested that differences in neutralizing titers may relate to the relative affinities of these antisera for the peptide conformation in the native structure.
我们合成了27种合成肽,这些肽对应于加德纳 - 阿恩斯坦B型猫白血病病毒(FeLV)编码gp70和p15E的序列的约80%。将这些肽与钥孔血蓝蛋白偶联,并注入兔子体内以制备抗肽抗血清。然后检测这些血清在体外中和多种FeLV分离株的能力。8种肽引发了针对B型分离株的中和反应。其中5种肽对应于gp70的序列,3种对应于p15E的序列。这些抗肽抗血清中和A型和C型FeLV的能力各不相同。在某些情况下,无法中和特定分离株与相应肽区域内的序列变化相对应。然而,四种优先中和B型病毒的抗体针对的是与萨尔马C型病毒共有的表位。这些结果表明,某些亚型的远端变化(可能是糖基化差异)相对于另一种病毒分离株改变了某些表位的可用性。我们制备了一组对应于gp70一个中和区域的重叠肽,并使用抗肽抗体和识别该表位的单克隆抗体进行斑点印迹分析。我们能够确定反应所需的一个五氨基酸序列。比较了抗合成肽抗体和对该表位有反应的单克隆抗体结合肽和病毒以及在体外中和病毒的能力。抗合成肽抗体和单克隆抗体都能以高滴度结合肽和病毒。然而,单克隆抗体对病毒的滴度比对抗合成肽抗体高4倍,中和滴度高10倍。用这两种抗体进行竞争试验,将它们调整到针对固定在组织培养板上的完整病毒体的等效抗病毒滴度。单克隆抗体具有更强的竞争病毒结合的能力,这表明中和滴度的差异可能与这些抗血清对天然结构中肽构象的相对亲和力有关。